50670-57-0

Upstream product

• 50670-49-0 4-bromo-4'-methylbiphenyl 
• 50670-58-1 4-formyl-4'-bromobiphenyl 
• 92-86-4 4-(4-bromophenyl)bromobenzene 
• 89901-03-1 methyl 4’-bromo-[1,1’-diphenyl]-4-carboxylate 
• 5467-74-3 4-Bromophenylboronic acid 
• 619-44-3 methyl 4-iodobenzoate 
• 84337-86-0 <4-(4-bromophenyl)phenyl>methanol 

Downstream Products

• 84337-86-0 <4-(4-bromophenyl)phenyl>methanol 
• 91587-32-5 1-(4'-Hydroxymethyl-biphenyl-4-yl)-2,2,6-trimethyl-cyclohexanol 
• 91587-09-6 4-<4-(2,6,6-trimethylcyclohexenyl)phenyl>benzoic acid 
• 91587-34-7 4'-(2,6,6-Trimethyl-cyclohex-1-enyl)-biphenyl-4-carboxylic acid methyl ester 
• 91587-33-6 methyl 4-<4-(1-hydroxy-2,2,6-trimethylcyclohexyl)phenyl>benzoate 

Relevant academic research and scientific papers

Helical Rod-like Phenylene Cages via Ruthenium Catalyzed Diol-Diene Benzannulation: A Cord of Three Strands

p-Bromo-terminated oligo(p-phenylenevinylenes) emanating from a 1,3,5-benzene core are dihydroxylated and subjected to ruthenium catalyzed diol-diene benzannulation to form tripodal oligo(phenylenes). Copper- or nickel-mediated 3-fold reductive biaryl homocoupling delivers a series of triple-stranded phenylene cages of helical rod-like topology bearing 14, 17, and 20 benzene rings.

Functionalised phosphonate ester supported lanthanide (Ln = La, Nd, Dy, Er) complexes

A series of phosphonate ester supported lanthanide complexes bearing functionalities for subsequent immobilisation on semiconductor surfaces are prepared. Six phosphonate ester ligands (L1-L6) with varying aromatic residues are synthesised. Subsequent com

PHENYL SUBSTITUTED CARBOXYLIC ACIDS

Disclosed are compounds and pharmaceutically acceptable salts of formula (A): which are useful in the treatment of metabolic disorders related to insulin resistance, leptin resistance, or hyperglycemia. Compounds of the invention include inhibitors of Protein tyrosine phosphatases, in particular Protein tyrosine phosphatase-1B (PTP-1B), that are useful in the treatment of diabetes and other PTP mediated diseases, such as cancer, neurodegenerative diseases and the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.

SUBSTITUTED AMINO CARBOXYLIC ACIDS

Disclosed are compounds and pharmaceutically acceptable salts of formula (I): which are useful in the treatment of metabolic disorders related to insulin resistance, leptin resistance, or hyperglycemia. Compounds of the invention include inhibitors of Protein tyrosine phosphatases, in particular Protein tyrosine phosphatase-1B (PTP-1B), that are useful in the treatment of diabetes and other PTP mediated diseases, such as cancer, neurodegenerative diseases and the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.

PHENYL SUBSTITUTED CARBOXYLIC ACIDS

Disclosed are compounds and pharmaceutically acceptable salts of formula (A): which are useful in the treatment of metabolic disorders related to insulin resistance, leptin resistance, or hyperglycemia. Compounds of the invention include inhibitors of Protein tyrosine phosphatases, in particular Protein tyrosine phosphatase-1B (PTP-1B), that are useful in the treatment of diabetes and other PTP mediated diseases, such as cancer, neurodegenerative diseases and the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.

Conformationally Restricted Retinoids

A series of conformationally restricted retinoids was synthesized and screened in two assays used to measure the ability of retinoids to control cell differentiation, namely, the reversal of keratinization in tracheal organ culture from vitamin A deficient hamsters and the inhibition of the induction of mouse epidermal ornithine decarboxylase by a tumor promoter.These compounds had bonds corresponding to selected bonds of the E-tetraene chain of retinoic acid (1) held in a planar cisoid conformation by inclusion in an aromatic ring.The meta-substituted analogue 3 of 4-benzoic acid (2) was far less active than 2 in both assays.In contrast, the vinyl homologue of 2 (4) and the 7,8-dihydro and 7,8-methano analogues (5 and 6) had activity comparable to that of 2.Analogues of 4-benzoic acid (7) were also screened.Replacement of the tetrahydronaphthalene ring of 7 by a benzonorbornenyl group (9) significantly reduced activity, as did removal of the vinylic methyl group from 9 (10).Replacement of the propenyl group of 9 by a cyclopropane ring (12) also reduced activity.Replacement of the tetrahydronaphthalene ring of 7 by 4,4-dimethyl-3,4-dihydro-2H-1-benzopyran and -benzothiopyran rings (13 and 14) also decreased activity.Inclusion of the 7,9 double bond system of 1 in an aromatic ring (15 and 16) reduced activity, whereas inclusion of the 5,7 double bond system in an aromatic ring enhanced activity (7 and 19).Inclusion of the 11,13 and 9,11,13 double bond systems in aromatic rings (2 and 18) also reduced activity below that of 1.Retinoic acid, 7, 13, 14, and 19 inhibited papilloma tumor formation in mice.Toxicity testing indicated that 7 was more toxic than 1, 13, 14, and 19, 19 was more toxic than 1, and 13 and 14 were less toxic than 1.